Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Consolidated Net Income: 2013-2025

Historic Consolidated Net Income for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Consolidated Net Income rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 144.15%. This contributed to the annual value of -$64.0 million for FY2024, which is 15.94% down from last year.
  • As of Q3 2025, Theravance Biopharma's Consolidated Net Income stood at $3.6 million, which was down 93.41% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Consolidated Net Income ranged from a high of $927.1 million in Q3 2022 and a low of -$23.1 million during Q4 2024.
  • In the last 3 years, Theravance Biopharma's Consolidated Net Income had a median value of -$12.7 million in 2024 and averaged -$6.8 million.
  • As far as peak fluctuations go, Theravance Biopharma's Consolidated Net Income soared by 4,400.00% in 2022, and later plummeted by 318.54% in 2023.
  • Over the past 5 years, Theravance Biopharma's Consolidated Net Income (Quarterly) stood at $25.8 million in 2021, then crashed by 84.90% to $3.9 million in 2022, then tumbled by 318.54% to -$8.5 million in 2023, then tumbled by 171.45% to -$23.1 million in 2024, then spiked by 128.47% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.5 million during Q1 2025.